RedHill Biopharma Ltd. (RDHL) NASDAQ

1.99

+0.01(+0.51%)

Updated at May 09 01:04PM

Currency In USD

RedHill Biopharma Ltd.

Address

21 Ha’arba’a Street

Tel Aviv, 6473921

Israel

Phone

972 3 541 3131

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

35

First IPO Date

January 07, 2013

Key Executives

NameTitlePayYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & Chief Executive Officer566,4651966
Dr. Reza Fathi Ph.D.Senior Vice President of Research & Development299,2911955
Mr. Adi FrishChief Corporate & Business Development Officer322,5921970
Mr. Guy Goldberg J.D.Chief Business Officer338,1261976
Mr. Razi IngberChief Financial Officer349,5081984
Mr. Gilead Raday MPhil, MScChief Operating Officer365,5561975
Mr. Rick D. ScruggsChief Commercial Officer & Director443,7361960
Ms. Alexandra OkmianSenior Business Development & Investor Relations Manager0N/A
Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory Affairs0N/A

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.